Good points CB, An inflection point, can be different things. A successful phase 2/3 healey trial would almost certainly result in a licensing deal or outright buy. And I can see why waiting for that event can be a good thing for those who are still holding at that stage. [More value] But some sort of funding deal whether it be a grant, or what ever prior to that would also be an inflection point. Albeit a smaller one.
Licensing deals are interesting however as they have milestones attached and always have a get out clause that the licensee can take advantage of. That will be more of a chance, if the soon to be released pre clinical work is something special. That they are now say publicly NUZ is a potential "disease Modifier" may be a clue there who knows ?
So maybe we will see a few smaller inflection points prior to the completion of the Healey trial.
Cheers
NUZ Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)